what is retatrutide used for Promises Big Weight Loss, but Safety Remains a Question The future of metabolic science

Published Phase 2 trial data (NEJM, 2023) demonstrated substantial reductions in body weight in some participants exceeding 20% over approximately 48 weeks making retatrutide one of the most potent agents currently in development for obesity and metabolic disease

Giugliano D, Scappaticcio L, Longo M, Bellastella G, Esposito K

Pharmacogenetics of New Classes of Antidiabetic Drugs. Bosnian Journal of Basic Medical Sciences, vol

For patients with type 2 diabetes, hemoglobin A1c should be measured at baseline and approximately every 3 months until glycemic targets are achieved, then at least twice yearly if stable

Which inflammatory markers do GLP-1 drugs affect

While Wegovy, or semaglutide , primarily targets weight loss and diabetes, its role in conjunction with Vyvanse remains worthy of consideration, especially since no direct interactions between the medications have been identified